American depositary shares of Vaccitech, which co-invented the COVID-19 vaccine developed by AstraZeneca Plc and Oxford University, fell nearly 20% in their market debut on Friday, giving the biotech firm a market value of about $464 million.
The company’s shares opened at $13.62, below the initial public offering price of $17.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.